|
|
Active Org.- |
|
Active Indication- |
|
Drug Highest PhasePending |
First Approval Ctry. / Loc.- |
First Approval Date20 Jan 1800 |
A Study of HSP90 Inhibitor AT13387 Alone and in Combination withCrizotinib in the Treatment of Non-small Cell Lung Cancer (NSCLC).
100 Clinical Results associated with HSP90B x MMP13 x IL-1β
100 Translational Medicine associated with HSP90B x MMP13 x IL-1β
0 Patents (Medical) associated with HSP90B x MMP13 x IL-1β